The Association Between Diabetes Mellitus and Risk of Sarcopenia: Accumulated Evidences From Observational Studies

• Published in: Frontiers in endocrinology (Lausanne) Vol. 12; p. 782391
• Main Authors: Qiao, Yu-Shun, Chai, Yin-He, Gong, Hong-Jian, Zhuldyz, Zhiyessova, Stehouwer, Coen D. A., Zhou, Jian-Bo, Simó, Rafael
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 23.12.2021
• Subjects: diabetes mellitus; Diabetes Mellitus - blood; Diabetes Mellitus - diagnosis; Diabetes Mellitus - epidemiology; diabetic complications; Endocrinology; Glycated Hemoglobin A - metabolism; HbA1c; Humans; Observational Studies as Topic - methods; observational study; prediabetes; Risk Factors; sarcopenia; Sarcopenia - blood; Sarcopenia - diagnosis; Sarcopenia - epidemiology; diabetic complications; diabetes mellitus; HbA1c; prediabetes; observational study; sarcopenia
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2021.782391

We performed a meta-analysis of observational studies to evaluate the association between the presence of sarcopenia and HbA1c, prediabetes, diabetes and diabetic complications. The PubMed, Embase, Cochrane and Web of Science databases were searched from inception to May 2021. We included full-text English language articles that reported the prevalence of sarcopenia in patients with and without diabetes. Quality assessment was performed according to the Newcastle- Ottawa scale for observational studies. Sixteen studies were included in the meta-analysis. Three studies showed that high HbA1c levels lead to loss of muscle mass, and one study involving prediabetes showed that people with prediabetes had lower muscle mass, strength, and performance than non-diabetic population. Seven studies showed that people with diabetes had a higher risk of sarcopenia than those without diabetes (combined OR: 2.09, 95% CI:1.62-2.70). The remaining five studies suggested that diabetic complications increased the risk of sarcopenia (combined OR: 2.09,95% CI:1.62-2.70). High HbA1c levels, prediabetes, diabetes and diabetes complications were associated with an increased risk of sarcopenia. Therapeutic strategies addressed to avoid the conversion of IGT to diabetes and to optimize glycemic control are warranted to prevent or arrest sarcopenia in the diabetic population.